T umour necrosis factor α (TNFα) has emerged as a potent proinflammatory mediator in the inflammatory arthritides. Studies on synovial tissue from patients with rheumatoid arthritis have shown not only the presence of large amounts of TNFα but also demonstrated its regulatory effect on the whole network of proinflammatory cytokines present in inflamed joints. 1 2 Consequently, TNFα antagonists given systemically have proved to be efficient in the treatment of chronic arthritides. 3 4 Here we report our experience of an attempt to ameliorate arthritis locally by intra-articular administration of TNFα antagonists. Six patients attending the department of rheumatology at Sahlgrenska University Hospital in Göteborg, who had persistent effusions in the knee joints which were non-responsive to intra-articular steroids, received a local injection of infliximab. Table 1 presents the diagnosis and clinical characteristics of the patients. Both the diagnosis and duration of the inflammatory joint disease were variable. All these patients had a low general activity of joint disease as assessed by the arthritis index, Health Assessment Questionnaire, low levels of acute phase reactants (erythrocyte sedimentation rate (ESR), C reactive protein), and the small numbers of white blood cells in the blood and synovial fluid. Persistent synovitis of a knee joint was the main clinical feature of their disease. A decision to inject TNFα antagonists locally was made after the persistent inflammation in the knee joint did not respond to two or more arthrocenteses with concomitant corticosteroid infusions during a period of six months. Patients gave their informed consent to intra-articular injection of the TNFα antagonists.
METHODS AND RESULTS
Infliximab (Remicade, 100 mg) was mixed with 10 ml sterile water according to the instructions for intravenous infusion, and the prepared solution was injected into the knee joint as a single dose. Synovial fluid (25-85 ml) was removed before the infliximab injection. The treatment was tolerated well by all the patients and no adverse reactions occurred locally in the injected knee or systemically during the follow up.
The effect of the infliximab injection was determined by clinical examination and by telephoning the patients. Five patients had a relapse of the synovitis in the injected knee within two weeks and the sixth patient within 6-7 weeks after the infliximab injection.
DISCUSSION
These results indicate that the effect of intra-articular treatment with TNFα antagonists was no better than the local injection of corticosteroids. Several reasons for this are possible:
• The degree of infusion of the antibodies is insufficient to bind the large amount of TNFα present in the synovial cavity.
Continuous local production and release of TNFα overcomes the neutralising capacity of the antibodies introduced.
• Antibodies injected into the joint neutralise only TNFα released into the synovial fluid, but do not penetrate into the synovial tissue or act on intracellular pools of TNFα.
• Complexes of anti-TNFα antibodies with TNFα can still reach receptors on the surface of target cells. A high local concentration of the immune complexes (anti-TNFα antibodies/TNFα) within the joint itself induces inflammation.
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• Local processes supporting inflammation within the joints are obviously not restricted to TNFα. The contribution of TNFα in local inflammation is less than its systemic effect. Anti-TNFα antibodies do not interrupt other mechanisms supporting inflammation within the joints.
The results of our uncontrolled study do not support the use of intra-articular TNFα inhibitors for the treatment of acute joint inflammation. Tc MDP) bone scan, carried out in secondary care, provided diagnostic information in patients with diffuse musculoskeletal pain of obscure origin, and whether scan findings correlated with clinical diagnosis. Clinical diagnosis, based on a minimum clinical follow up of two years or at least one year after the scan, was used as a reference or "gold standard".
METHODS AND RESULTS
Criteria for inclusion were the presence of diffuse musculoskeletal pain; a scan for diagnostic uncertainty; and availability of whole body scans, including a close-up scan of the peripheral joints. Three hour images were studied. Earlier "blood pool" images were not available. Patients were excluded if scans had been carried out for a regional disorder, isolated spinal disease, Paget's disease, suspected malignancy, known arthritis or connective tissue disease, and previous disease modifying antirheumatic drug use. One researcher examined the medical records and applied the inclusion and exclusion criteria. Ethics committee approval was granted.
Two consultant radiologists read all the scans independently without reference to clinical data or the original scan report, to ensure consistency. Scans were classified according to the scheme shown in table 1. Radiologists then met to agree a final classification, which was used against our reference standard. General practitioner records were reviewed if follow up data were inadequate in the hospital records (10 cases). Two researchers agreed the final clinical diagnosis by discussion and after independent review of the records.
Three hundred and ten 99m
Tc MDP bone scans were ordered between May 1995 and August 1996, but only 135 films were available. One hundred and twenty isotope scans were found, 54 patients met inclusion criteria, but four were excluded because of incomplete records (table 1) . Radiologists agreed on scan classification in 20/50 (40%) cases (κ for inflammatory arthritis versus other categories 0.31). However, after conferring, the radiologists readily agreed and discrepancies arose because of difficulties in classifying osteoarthritis versus non-specific isotope uptake.
The sensitivity of an isotope bone scan for a clinical diagnosis of " inflammatory arthritis" was 13% (agreement in 2/15; 95% confidence interval (CI) 4% to 23%; χ 2 =0.57; p>0.1) and the specificity 80% (agreement in 28/35; 95% CI 69% to 91%).
The likelihood ratio of a positive scan was 0.65 and 1.09 for a negative scan. The positive predictive value of a bone scan was 22% and the negative predictive value 68%. The latter suggests that scans may be useful in excluding inflammatory arthritis, a finding consistent with an earlier report. 1 
DISCUSSION
Our study fell short of the ideal design for assessing the accuracy of a diagnostic test in that it was not a prospective blind comparison of a test and a reference standard in consecutive patients. 2 A practical difficulty in meeting this requirement was that clinical follow up could not be applied in parallel with the test. Also, we studied relatively few patients and many films were not found. Possibly, the final clinical diagnosis was influenced by the bone scan report. Such "test review bias" is difficult to remove in evaluations of routine diagnostic tests 
